CJ-2360 is a Potent and Orally Active ALK Inhibitor
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor (IR) kinase superfamily. It highly expresses in adult brain tissue and exerts an important role in the development of the nervous system. Deregulation of ALK originally presents by the identification of at (2;5) chromosomal translocation...
TL13-12 is a Selective ALK-PROTAC Degrader
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. ALK is an attractive target for cancer therapies not only for its prominent role in a number of malignancies but also for its scant expression in normal adult tissue. Therapeutic strategies that target ALK may provide ways to further delay...
TL13-112 is a PROTAC Degrader of ALK
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its mutation in domains. ALK Chromosomal translocations involve the kinase domain of ALK in many cancers. In addition to ALCL, ALK fusion proteins are seen in diffuse large B-cell lymphoma (DLBCL), inflammatory myofibroblastic tumor (IMT), breast cancer, colorectal cancer,...
MS4077 is an Anaplastic Lymphoma Kinase PROTAC (Degrader)
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, which belongs to the insulin receptor kinase subfamily. ALK correlates with oncogenesis in different types of cancers, such as anaplastic large-cell non-Hodgkin’s lymphoma (ALCL), non-small-cell lung cancer (NSCLC), squamous cell carcinoma (SCC), renal cell carcinoma (RCC), thyroid cancer, breast cancer,...